Product Description: Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Sandra Rayego-Mateos, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2022 Dec 5:S0085-2538(22)01017-1.